Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

451 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trial.
Recourt K, van der Aart J, Jacobs G, de Kam M, Drevets W, van Nueten L, Kanhai K, Siebenga P, Zuiker R, Ravenstijn P, Timmers M, van Gerven J, de Boer P. Recourt K, et al. Among authors: de kam m, de boer p. J Psychopharmacol. 2020 Sep;34(9):1030-1042. doi: 10.1177/0269881120914206. Epub 2020 Apr 4. J Psychopharmacol. 2020. PMID: 32248747 Clinical Trial.
A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity.
De Boer P, Drevets WC, Rofael H, van der Ark P, Kent JM, Kezic I, Parapatics S, Dorffner G, van Gerven J, Beneš H, Keicher C, Jahn H, Seiden DJ, Luthringer R. De Boer P, et al. J Psychopharmacol. 2018 Jun;32(6):668-677. doi: 10.1177/0269881118773745. Epub 2018 May 31. J Psychopharmacol. 2018. PMID: 29848147 Clinical Trial.
Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants.
Timmers M, Ravenstijn P, Xi L, Triana-Baltzer G, Furey M, Van Hemelryck S, Biewenga J, Ceusters M, Bhattacharya A, van den Boer M, van Nueten L, de Boer P. Timmers M, et al. Among authors: de boer p. J Psychopharmacol. 2018 Dec;32(12):1341-1350. doi: 10.1177/0269881118800067. Epub 2018 Sep 27. J Psychopharmacol. 2018. PMID: 30260294 Clinical Trial.
The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia.
Brooks S, Jacobs GE, de Boer P, Kent JM, Van Nueten L, van Amerongen G, Zuiker R, Kezic I, Luthringer R, van der Ark P, van Gerven JM, Drevets W. Brooks S, et al. Among authors: de boer p. J Psychopharmacol. 2019 Feb;33(2):202-209. doi: 10.1177/0269881118822258. Epub 2019 Jan 15. J Psychopharmacol. 2019. PMID: 30644312 Clinical Trial.
The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder.
Recourt K, de Boer P, Zuiker R, Luthringer R, Kent J, van der Ark P, Van Hove I, van Gerven J, Jacobs G, van Nueten L, Drevets W. Recourt K, et al. Among authors: de boer p. Transl Psychiatry. 2019 Sep 3;9(1):216. doi: 10.1038/s41398-019-0553-z. Transl Psychiatry. 2019. PMID: 31481683 Free PMC article. Clinical Trial.
The effects of a glycine reuptake inhibitor R231857 on the central nervous system and on scopolamine-induced impairments in cognitive and psychomotor function in healthy subjects.
Liem-Moolenaar M, Zoethout RW, de Boer P, Schmidt M, de Kam ML, Cohen AF, Franson KL, van Gerven JM. Liem-Moolenaar M, et al. Among authors: de boer p, de kam ml. J Psychopharmacol. 2010 Nov;24(11):1681-7. doi: 10.1177/0269881109105573. Epub 2009 Jul 31. J Psychopharmacol. 2010. PMID: 19648218 Clinical Trial.
The effects of the glycine reuptake inhibitor R213129 on the central nervous system and on scopolamine-induced impairments in psychomotor and cognitive function in healthy subjects.
Liem-Moolenaar M, Zoethout RW, de Boer P, Schmidt M, de Kam ML, Cohen AF, Franson KL, van Gerven JM. Liem-Moolenaar M, et al. Among authors: de boer p, de kam ml. J Psychopharmacol. 2010 Nov;24(11):1671-9. doi: 10.1177/0269881109106942. Epub 2010 Feb 8. J Psychopharmacol. 2010. PMID: 20142308 Clinical Trial.
451 results